UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): October 5,
2020
GT Biopharma, Inc.
(Exact
name of Registrant as specified in its charter)
|
Delaware
(State
or other Jurisdiction of
Incorporation
or organization)
|
000-08092
(Commission
File Number)
|
94-1620407
(IRS
Employer I.D. No.)
|
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212
Phone: (800) 304-9888
(Address,
including zip code, and telephone number, including area code,
of
registrant’s
principal executive offices)
N/A
(Former
name, former address and former fiscal year, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l
4a- l 2)
☐
Pre-commencement
communications pursuant to Rule l 4d-2(b) under the Exchange Act
(17 CFR 240. l 4d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240. l 3e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
|
None
|
N/A
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. Entry into a Material Definitive Agreement.
Effective October 5, 2020, the Registrant, GT Biopharma, Inc. (the
“Company”), entered into a Master Services Agreement
(the “Agreement”), with Cytovance Biologics, Inc.,
(“Cytovance”), a subsidiary of Shenzhen Hepalink
Pharmaceutical Group Co., Ltd. Cytovance is headquartered in
Oklahoma City, Oklahoma.
Under the Agreement, the Company will engage Cytovance as the
exclusive manufacture for three of the Company’s TriKE™
therapeutic product candidates. Cytovance will manufacture
TriKE™ using Cytovance’s proprietary Keystone®
bacterial or mammalian expression systems. Subject to the
completion of certain milestones by Cytovance, GT Biopharma has the
option to pay Cytovance up to $6 million for its manufacturing
services in either cash or in shares of the Company’s common
stock valued at the time Cytovance achieves each of several
milestones over the next 12 months.
Item 9.01 Exhibits.
(d)
Exhibits
|
No.
|
Description
|
|
|
|
|
|
Master
Services Agreement
|
|
|
|
|
|
Press
Release
|
SIGNATURE PAGE
Pursuant
to the requirement of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GT Biopharma, Inc.
|
|
|
|
|
|
|
|
|
Dated:
October 6, 2020
|
|
By:
|
/s/
Steven Weldon
|
|
|
|
|
|
Steven
Weldon
|
|
|
|
|
|
Chief
Financial Officer
|
|